BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
The most effective method to Make a Dazzling Site in 5 Basic Advances- Eating ultra-processed foods could raise precancerous polyp risk for women under 50, according to research
- Are your hormones imbalanced? Doctors explain how to know if you need testing
- vote in favor of Your #1 kind of climate
- Qatar, Ireland accuse Israel of using chemical weapons on Palestinians, demand watchdog probe use
- Top Music and Dance Celebration: Which One Gets You Going?
- Pedal Power: Divulging Well known Bike Brands for Each Cyclist
- Steinmeier honours Italian 'guest workers' who rebuilt German economy
- Tremendous Spelunking: Cool Caverns All over the Planet
